Zydus Cadila gets USFDA nod to market Telmisartan tablets in US
Date: 01-09-2014Pharma major, Zydus Cadila has received the final approval from the US drug regulator -- US Food and Drug Administration (USFDA) -- to market Telmisartan tablets of 20mg, 40mg and 80mg in the US market.
The estimated sales in 2014 for Telmisartan tablets, which fall in the anti-hypertensive segment is $233.3 million, as per IMS. The group now has 96 approvals and has so far filed 249 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.